Nature 1994, 369:756–758.PubMedCrossRef

14. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S: Nutlin-3a cell line rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998, 273:14424–14429.PubMedCrossRef 15. Lei W, Jia T, Su Z, Wen W, Zhu X: Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro. Oncol Res 2009, 18:73–81.PubMedCrossRef 16. Calabro A, Tai J, Allen SL, Budman DR: In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 2008, 19:705–712.PubMedCrossRef 17. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P: Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005, 19:2153–2158.PubMedCrossRef LY2835219 Smoothened inhibitor 18. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol

3-kinase/protein kinase B inhibitors. Cancer Res 2005, 65:3336–3346.PubMed 19. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004, 10:7031–7042.PubMedCrossRef 20. Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, Wang H, Huang X, Wong ST, Wang Y, et al.: Treating triple-negative

breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 2010, 46:1132–1143.PubMedCrossRef buy Doxorubicin 21. Yang Z, Lei Z, Li B, Zhou Y, Zhang GM, Feng ZH, Zhang B, Shen GX, Huang B: Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci 2010, 101:494–500.PubMedCrossRef 22. Niu H, Li H, Xu C, He P: Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep 2010, 24:465–471.PubMed 23. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, et al.: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836–1843.PubMedCrossRef 24. Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, et al.: Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010, 116:3903–3909.PubMedCrossRef 25. Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381–395.PubMedCrossRef 26.